# BioNexus Gene Lab Corp (BGLC)

Source: https://www.quantisnow.com/company/BGLC
Generated: 2026-11-14T14:20:12.256Z

- Ticker: BGLC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical Specialities
- SEC CIK: 0001737523

## Latest BGLC news and filings

- 2026-10-30 13:00 UTC [BioNexus Launches New Corporate Website with Expanded Business and Investor Resources](https://www.quantisnow.com/insight/bionexus-launches-new-corporate-website-with-expanded-business-and-investor-6764739)
- 2026-10-07 13:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-bionexus-gene-lab-corp-6739988)
- 2026-10-05 13:00 UTC [RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab](https://www.quantisnow.com/insight/ryet-to-enter-malaysian-healthcare-through-exclusive-cogni-ai-license-6736183)
- 2026-08-14 21:20 UTC [SEC Form 4] [Chief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-tan-lee-su-leng-was-granted-338709-shares-6683729)
- 2026-08-14 21:19 UTC [SEC Form 4] [Director Yap Chee Keong was granted 32,258 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-yap-chee-keong-was-granted-32258-shares-sec-form-6683721)
- 2026-08-14 21:18 UTC [SEC Form 4] [Director Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-bin-abdul-hamid-muhammad-azrul-was-granted-32258-shares-6683709)
- 2026-08-14 21:17 UTC [SEC Form 4] [Chief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-chong-set-fui-was-granted-96774-shares-6683705)
- 2026-08-14 21:14 UTC [SEC Form 4] [Director Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)](https://www.quantisnow.com/insight/director-low-jook-yuen-was-granted-16129-shares-increasing-direct-6683672)
- 2026-08-14 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bionexus-gene-lab-corp-6683591)
- 2026-08-07 20:28 UTC [SEC Form 3] [New insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-fidelion-diagnostics-pte-ltd-claimed-ownership-of-392329-6671784)
- 2026-07-31 21:52 UTC [SEC Form 3] [New insider Tan Lee Su-Leng claimed no ownership of stock in the company (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-tan-lee-su-leng-claimed-no-ownership-of-stock-6658293)
- 2026-07-31 21:50 UTC [SEC Form 3] [New insider Bin Abdul Hamid Muhammad Azrul claimed no ownership of stock in the company (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-bin-abdul-hamid-muhammad-azrul-claimed-no-ownership-6658291)
- 2026-07-31 21:03 UTC [SEC Form 3] [New insider Yap Chee Keong claimed no ownership of stock in the company (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-yap-chee-keong-claimed-no-ownership-of-stock-6658193)
- 2026-07-31 21:02 UTC [SEC Form 3] [New insider Low Jook Yuen claimed ownership of 1,261 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-low-jook-yuen-claimed-ownership-of-1261-shares-6658189)
- 2026-07-31 21:00 UTC [SEC Form 3] [New insider Chong Set Fui claimed no ownership of stock in the company (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-chong-set-fui-claimed-no-ownership-of-stock-6658175)
- 2026-07-28 18:30 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-other-events-6651219)
- 2026-07-28 13:00 UTC [Conference Announcement] [BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit](https://www.quantisnow.com/insight/bionexus-advances-vitaguard-southeast-asia-rollout-following-china-working-visit-6650899)
- 2026-06-05 13:00 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-other-events-6590699)
- 2026-05-29 13:00 UTC [BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-calls-for-malaysiachina-biotechnology-cooperation-to-6578531)
- 2026-05-15 21:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bionexus-gene-lab-corp-6558420)
- 2026-04-14 21:20 UTC [SEC Form 10-K] [SEC Form 10-K filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-bionexus-gene-lab-corp-6499988)
- 2026-03-31 21:25 UTC [SEC Form NT 10-K filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-bionexus-gene-lab-corp-6480035)
- 2026-03-17 18:30 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-regulation-fd-6451965)
- 2026-03-11 12:45 UTC [Conference Announcement] [BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-announces-appointment-of-dr-muthu-meyyappan-6441366)
- 2026-02-23 13:35 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-other-events-6406334)
- 2026-02-23 13:30 UTC [Leadership Update] [BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-completes-chemrex-governance-restructuring-appoints-matthew-6406267)
- 2026-02-03 21:10 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-other-events-6372331)
- 2026-01-28 14:00 UTC [BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market](https://www.quantisnow.com/insight/bionexus-launches-regional-deployment-of-vitaguard-mrd-infrastructure-positioned-to-6363507)
- 2025-12-30 18:30 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-submission-of-6329679)
- 2025-12-23 22:20 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-other-events-6327200)
- 2025-12-03 22:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-bionexus-gene-lab-corp-6302140)
- 2025-12-03 13:45 UTC [BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-completes-strategic-investment-in-fidelion-diagnostics-6300942)
- 2025-12-02 13:05 UTC [Conference Announcement] [BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-nasdaq-bglc-secures-500-million-equity-6298882)
- 2025-12-02 13:00 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-entry-into-6298866)
- 2025-12-01 13:00 UTC [BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-nasdaq-bglc-and-fidelion-diagnostics-execute-6296901)
- 2025-11-14 22:21 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bionexus-gene-lab-corp-6281460)
- 2025-11-14 21:23 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by BioNexus Gene Lab Corp](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-bionexus-gene-lab-corp-6280789)
- 2025-11-13 13:00 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-entry-into-6276256)
- 2025-11-12 13:32 UTC [SEC Form 8-K] [BioNexus Gene Lab Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-filed-sec-form-8-k-entry-into-6273156)
- 2025-11-12 13:00 UTC [BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization](https://www.quantisnow.com/insight/bionexus-gene-lab-corp-nasdaq-bglc-announces-strategic-agreements-with-6272949)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BGLC
- Earnings history: https://www.quantisnow.com/earnings/BGLC
- Dividend history: https://www.quantisnow.com/dividends/BGLC
- Insider transactions: https://www.quantisnow.com/insiders/BGLC
- Options chain: https://www.quantisnow.com/options/BGLC
- SEC 8-K filings only: https://www.quantisnow.com/company/BGLC/8-k
- RSS and alerts for BGLC: https://www.quantisnow.com/docs/rss-feeds.md